|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for MAP3K7 |
 Gene summary |
| Basic gene Info. | Gene symbol | MAP3K7 |
| Gene name | mitogen-activated protein kinase kinase kinase 7 | |
| Synonyms | MEKK7|TAK1|TGF1a | |
| Cytomap | UCSC genome browser: 6q15 | |
| Type of gene | protein-coding | |
| RefGenes | NM_003188.3, NM_145331.2,NM_145332.2,NM_145333.2, | |
| Description | TGF-beta activated kinase 1TGF-beta-activated kinase 1transforming growth factor-beta-activated kinase 1 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 602614 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000135341 | ||
| HPRD : 04011 | ||
| Vega : OTTHUMG00000015217 | ||
| Protein | UniProt: O43318 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_MAP3K7 | |
| BioGPS: 6885 | ||
| Pathway | NCI Pathway Interaction Database: MAP3K7 | |
| KEGG: MAP3K7 | ||
| REACTOME: MAP3K7 | ||
| Pathway Commons: MAP3K7 | ||
| Context | iHOP: MAP3K7 | |
| ligand binding site mutation search in PubMed: MAP3K7 | ||
| UCL Cancer Institute: MAP3K7 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0000186 | activation of MAPKK activity | 8663074 | GO:0000187 | activation of MAPK activity | 9079627 | GO:0007252 | I-kappaB phosphorylation | 11460167 | GO:0007254 | JNK cascade | 9079627 | GO:0043507 | positive regulation of JUN kinase activity | 11460167 | GO:0043966 | histone H3 acetylation | 18838386 | GO:0051403 | stress-activated MAPK cascade | 9079627 |
| Top |
| Ligand binding site mutations for MAP3K7 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | L81 | R83C | COAD | 1 | G45 | G45V | OV | 1 | V90 | V90A | UCEC | 1 | L81,E77 | R79W | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for MAP3K7 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | G45 | G45V | 0.13892212 | V90 | V90A | -1.3763209 | L81 | R83C | -0.99819243 | L81 | R79W | -0.33334362 | E77 | R79W | -0.33334362 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for MAP3K7 from PDB |
| Top |
| Differential gene expression and gene-gene network for MAP3K7 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for MAP3K7 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0017661 | Glomerulonephritis, IGA | 1 | Biomarker |
| umls:C0033578 | Prostatic Neoplasms | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for MAP3K7 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of MAP3K7 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | YIY | (1E)-1-[5-TERT-BUTYL-2-(3-FLUOROPHENYL)-1H- PYRAZOL-3-YLIDENE]-3-(4-PYRIDIN-3-YLOXYPHENYL) UREA | 2yiy | A | E77 L81 V90 | ADN | ADENOSINE | 2eva | A | G45 |
| Top |
| Conservation information for LBS of MAP3K7 |
| Multiple alignments for O43318 in multiple species |
| LBS | AA sequence | # species | Species | A107 | LVMEYAEGGSL | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | A61 | RAKDVAIKQIE | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | E105 | VCLVMEYAEGG | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | E77 | KAFIVELRQLS | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | G43 | VEEVVGRGAFG | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | G45 | EVVGRGAFGVV | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | H154 | PKALIHRDLKP | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | I173 | GTVLKICDFGT | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | L163 | KPPNLLLVAGG | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | L81 | VELRQLSRVNH | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | M104 | PVCLVMEYAEG | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | P160 | RDLKPPNLLLV | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | R44 | EEVVGRGAFGV | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | S111 | YAEGGSLYNVL | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | V50 | GAFGVVCKAKW | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | V76 | RKAFIVELRQL | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | V90 | NHPNIVKLYGA | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | Y106 | CLVMEYAEGGS | 3 | Homo sapiens, Rattus norvegicus, Bos taurus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |